Skip Navigation


IJE Advance Access originally published online on October 17, 2008
International Journal of Epidemiology 2009 38(1):217-231; doi:10.1093/ije/dyn217
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow An erratum has been published
Right arrow All Versions of this Article:
38/1/217    most recent
dyn217v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Shah, T.
Right arrow Articles by Hingorani, A. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shah, T.
Right arrow Articles by Hingorani, A. D
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2008; all rights reserved.

Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts

Tina Shah1,{dagger}, Juan P Casas2,{dagger}, Jackie A Cooper1, Ioanna Tzoulaki3, Reecha Sofat1, Valerie McCormack2, Liam Smeeth2, John E Deanfield4, Gordon D Lowe5, Ann Rumley5, F Gerald R Fowkes6, Steve E Humphries1 and Aroon D Hingorani1,7,*

1Centre for Clinical Pharmacology, University College London, London, UK.
2Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
3Department of Epidemiology and Public Health, Imperial College London, London, UK.
4Vascular Physiology Unit, Institute of Child Health, University College London, UK.
5Division of Cardiovascular and Medical Sciences, University of Glasgow, Royal Infirmary, Glasgow, UK.
6Wolfson Unit for Prevention of Peripheral Vascular Diseases, Public Health Sciences, University of Edinburgh, Edinburgh, UK.
7Department of Epidemiology and Public Health, University College London, London, UK.

*Corresponding author. Centre for Clinical Pharmacology, British Heart Foundation Laboratories at UCL, London WC1E 6JJ, UK. E-mail: a.hingorani{at}ucl.ac.uk


   Abstract

Background Non-uniform reporting of relevant relationships and metrics hampers critical appraisal of the clinical utility of C-reactive protein (CRP) measurement for prediction of later coronary events.

Methods We evaluated the predictive performance of CRP in the Northwick Park Heart Study (NPHS-II) and the Edinburgh Artery Study (EAS) comparing discrimination by area under the ROC curve (AUC), calibration and reclassification. We set the findings in the context of a systematic review of published studies comparing different available and imputed measures of prediction. Risk estimates per-quantile of CRP were pooled using a random effects model to infer the shape of the CRP-coronary event relationship.

Results NPHS-II and EAS (3441 individuals, 309 coronary events): CRP alone provided modest discrimination for coronary heart disease (AUC 0.61 and 0.62 in NPHS-II and EAS, respectively) and only modest improvement in the discrimination of a Framingham-based risk score (FRS) (increment in AUC 0.04 and –0.01, respectively). Risk models based on FRS alone and FRS + CRP were both well calibrated and the net reclassification improvement (NRI) was 8.5% in NPHS-II and 8.8% in EAS with four risk categories, falling to 4.9% and 3.0% for 10-year coronary disease risk threshold of 15%. Systematic review (31 prospective studies 84 063 individuals, 11 252 coronary events): pooled inferred values for the AUC for CRP alone were 0.59 (0.57, 0.61), 0.59 (0.57, 0.61) and 0.57 (0.54, 0.61) for studies of <5, 5–10 and >10 years follow up, respectively. Evidence from 13 studies (7201 cases) indicated that CRP did not consistently improve performance of the Framingham risk score when assessed by discrimination, with AUC increments in the range 0–0.15. Evidence from six studies (2430 cases) showed that CRP provided statistically significant but quantitatively small improvement in calibration of models based on established risk factors in some but not all studies. The wide overlap of CRP values among people who later suffered events and those who did not appeared to be explained by the consistently log-normal distribution of CRP and a graded continuous increment in coronary risk across the whole range of values without a threshold, such that a large proportion of events occurred among the many individuals with near average levels of CRP.

Conclusions CRP does not perform better than the Framingham risk equation for discrimination. The improvement in risk stratification or reclassification from addition of CRP to models based on established risk factors is small and inconsistent. Guidance on the clinical use of CRP measurement in the prediction of coronary events may require updating in light of this large comparative analysis.


Keywords C-reactive protein, prediction, coronary heart disease, primary prevention, risk stratification


{dagger}These authors contributed equally to this work.

Accepted 3 September 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
JAMAHome page
A. D. Hingorani and B. M. Psaty
Primary Prevention of Cardiovascular Disease: Time to Get More or Less Personal?
JAMA, November 18, 2009; 302(19): 2144 - 2145.
[Full Text] [PDF]


Home page
Am J EpidemiolHome page
J. Pirkola, M. Vaarasmaki, M. Ala-Korpela, A. Bloigu, D. Canoy, A.-L. Hartikainen, M. Leinonen, S. Miettola, M. Paldanius, T. H. Tammelin, et al.
Low-Grade, Systemic Inflammation in Adolescents: Association With Early-Life Factors, Gender, and Lifestyle
Am. J. Epidemiol., November 16, 2009; (2009) kwp320v1.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
J S Rana, M Cote, J-P Despres, M S Sandhu, P J Talmud, E Ninio, N J Wareham, J J P Kastelein, A H Zwinderman, K-T Khaw, et al.
Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study
Heart, October 15, 2009; 95(20): 1682 - 1687.
[Abstract] [Full Text] [PDF]


Home page
J Med ScreenHome page
D. S Wald and J. P Bestwick
Carotid ultrasound screening for coronary heart disease: results based on a meta-analysis of 18 studies and 44,861 subjects
J Med Screen, September 1, 2009; 16(3): 147 - 154.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
P. Elliott, J. C. Chambers, W. Zhang, R. Clarke, J. C. Hopewell, J. F. Peden, J. Erdmann, P. Braund, J. C. Engert, D. Bennett, et al.
Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease
JAMA, July 1, 2009; 302(1): 37 - 48.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. R. Cockcroft, C. M. McEniery, I. B. Wilkinson, and Y. Ben-Shlomo
Response to Polymorphisms of Inflammatory Markers/Mediators and Arterial Stiffness
Hypertension, June 1, 2009; 53(6): e40 - e40.
[Full Text] [PDF]


Home page
Int J EpidemiolHome page
R. S Vasan
Commentary: C-reactive protein and risk prediction--moving beyond associations to assessing predictive utility and clinical usefulness
Int. J. Epidemiol., February 1, 2009; 38(1): 231 - 234.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.